New PET tracer aims to spot Alzheimer's plaques safely
NCT ID NCT05731440
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new radioactive tracer called Fluselenamyl for PET scans to detect beta-amyloid plaques in the brain, a hallmark of Alzheimer's disease. Researchers will check its safety and how well it works in 60 healthy volunteers and people with mild cognitive impairment or Alzheimer's. The goal is to improve diagnosis by comparing this new tracer with an existing one.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
18F-Fluselenamyl (a radioactive tracer for PET scans)
What this could lead to
If successful, this could provide a safer and more accessible way to detect Alzheimer's-related brain changes early, aiding diagnosis and research.
What could go wrong
This is an early-phase safety and imaging study with only 60 participants. The tracer may not prove more effective than existing methods, and results may not apply to all populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States